CN Patent

CN101528231A — 在癌症的治疗中使用pi3k和mek调控剂

Assigned to Exelixis Inc · Expires 2009-09-09 · 17y expired

What this patent protects

本发明提供了利用抑制激酶、更具体地说抑制MEK和PI3K的化合物的组合来治疗癌症的方法。

USPTO Abstract

本发明提供了利用抑制激酶、更具体地说抑制MEK和PI3K的化合物的组合来治疗癌症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN101528231A
Jurisdiction
CN
Classification
—
Expires
2009-09-09
Drug substance claim
No
Drug product claim
No
Assignee
Exelixis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.